risperidone
Phase 3- Indications
- Schizophrenia, Bipolar 1 disorder
Company intelligence / Profile preview
Lyndra’s lead candidate—oral weekly risperidone—achieved a phase III efficacy win in adult patients with schizophrenia and schizoaffective disorder as of January 2024. The study was stopped early due to positive interim results showing comparable efficacy to daily Risperdal. A phase III safety trial will begin in the first half of 2025. The LYNX platform has demonstrated clinical proof-of-concept across five therapeutic areas using over twenty-five APIs.
3 more assets in the full pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lyndra Therapeutics.